share_log

華領醫藥-B：中期報告2024

HUA MEDICINE-B: INTERIM REPORT 2024

HKEX ·  Sep 26, 2024 04:37

Summary by Moomoo AI

華領醫藥-B於2024年6月30日發布中期報告，顯示其2型糖尿病藥物华堂宁®銷量顯著增長。該藥物於2023年11月納入國家醫保藥品目錄，並於2024年1月1日在中國內地全國報銷生效。與拜耳醫藥保健有限公司及80家一級分銷商合作，推廣至31個省及直轄市。2024年上半年銷量達846,000盒，較上年同期增加634,000盒。銷售收入達人民幣102.7百萬元，毛利率為46.5%，但由於國家醫保藥品目錄降價，毛利率較去年同期下降。公司預計隨著生產規模擴大，毛利率將上升。上市後臨床研究進展順利，並在美國開展HMS1005的I期研究。期內虧損為人民幣142.2百萬元，研發開支增加至人民幣119.8百萬元。截至報告期末，公司現金及現金等價物為人民幣1,338.8百萬元。
華領醫藥-B於2024年6月30日發布中期報告，顯示其2型糖尿病藥物华堂宁®銷量顯著增長。該藥物於2023年11月納入國家醫保藥品目錄，並於2024年1月1日在中國內地全國報銷生效。與拜耳醫藥保健有限公司及80家一級分銷商合作，推廣至31個省及直轄市。2024年上半年銷量達846,000盒，較上年同期增加634,000盒。銷售收入達人民幣102.7百萬元，毛利率為46.5%，但由於國家醫保藥品目錄降價，毛利率較去年同期下降。公司預計隨著生產規模擴大，毛利率將上升。上市後臨床研究進展順利，並在美國開展HMS1005的I期研究。期內虧損為人民幣142.2百萬元，研發開支增加至人民幣119.8百萬元。截至報告期末，公司現金及現金等價物為人民幣1,338.8百萬元。
Huali Pharmaceutical-B released its interim report on June 30, 2024, showing a significant increase in sales of its type 2 diabetes drug Huatangning®. The drug was included in the national medical insurance drug list in November 2023 and became nationally reimbursed in mainland China on January 1, 2024. It has collaborated with Bayer Healthcare Limited and 80 primary distributors to promote the drug in 31 provinces and municipalities directly under the central government. Sales in the first half of 2024 reached 846,000 boxes, an increase of 634,000 boxes compared to the same period last year. Sales revenue amounted to RMB 102.7 million, with a gross margin of 46.5%. However, due to the price reduction in the national medical insurance drug list, the gross margin decreased compared to the same period last year...Show More
Huali Pharmaceutical-B released its interim report on June 30, 2024, showing a significant increase in sales of its type 2 diabetes drug Huatangning®. The drug was included in the national medical insurance drug list in November 2023 and became nationally reimbursed in mainland China on January 1, 2024. It has collaborated with Bayer Healthcare Limited and 80 primary distributors to promote the drug in 31 provinces and municipalities directly under the central government. Sales in the first half of 2024 reached 846,000 boxes, an increase of 634,000 boxes compared to the same period last year. Sales revenue amounted to RMB 102.7 million, with a gross margin of 46.5%. However, due to the price reduction in the national medical insurance drug list, the gross margin decreased compared to the same period last year. The company expects the gross margin to increase as production scale expands. Clinical research progress has been smooth after the market launch, with Phase I studies of HMS1005 initiated in the USA. The loss during the period was RMB 142.2 million, with research and development expenses increasing to RMB 119.8 million. As of the end of the reporting period, the company's cash and cash equivalents amounted to RMB 1,338.8 million.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    VIVA BIOTECH
    01873
    -- 1.530
    JW THERAP-B
    02126
    -- 1.980
    EVEREST MED-B
    01952
    -- 42.450
    TYK MEDICINES-B
    02410
    -- 27.000
    AUSTAR
    06118
    -- 0.640
    Log In for the Full List
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
    Discussing
    Tesla's earnings caused fluctuations, what's your market outlook？
    Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
    TSLA earnings preview: Grab rewards by guessing the opening price!